Product Information
LOXAPINE 50 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.9520 per EA under NDC 00591037201. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 15, 1988. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
00591037201
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LOXAPINE SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA072062FDA Approved
6/15/1988
TE Code
AB
On Market Since
6/15/1988
Price Statistics
The NADAC for LOXAPINE 50 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.9520 per EA |
|---|---|
| All-time high | $1.4265 (Jun 14, 2023) |
| All-time low | $0.7084 (Sep 19, 2018) |
| 52-week high | $0.9799 |
| 52-week low | $0.8779 |
| Median price | $0.8820 |
| Average price | $0.8940 |
| Largest weekly change | +41.3% (Feb 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Loxapine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LOXAPINE 50 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for LOXAPINE 50 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.9520 per EA (NDC 00591037201), effective Sep 30, 2026.
How has the price of LOXAPINE 50 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for LOXAPINE 50 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for LOXAPINE 50 MG CAPSULE?
Since Nov 28, 2013, the NADAC for LOXAPINE 50 MG CAPSULE has ranged from a low of $0.7084 (Sep 19, 2018) to a high of $1.4265 (Jun 14, 2023), with a median of $0.8820 per EA.
Are there cheaper alternatives to LOXAPINE 50 MG CAPSULE?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LOXAPINE 50 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures LOXAPINE 50 MG CAPSULE?
LOXAPINE 50 MG CAPSULE (NDC 00591037201) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.